stockrow
Friday 6 November 2026
Export NEO’s income statement to Excel — free account
NeoGenomics, Inc.
NEO Healthcare Diagnostics & Research
NeoGenomics, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $727.3 million, up 10.1% from fiscal 2024.
- Revenue
- +11.4%
- EPS
- +72.1%
- Free cash flow
- −3,724.2%
- Total debt
- +10.9%
Quarter to September 2026, against a year earlier
16.55
0.60
−3.50%
Follow NEO
Alert me
| Sep '26 | Jun '26 | Mar '26 | Dec '25 | Older periods | |
|---|---|---|---|---|---|
P/E ratio |
0.00 | 0.00 | 0.00 | 0.00 |
+8 more quarters Free account |
P/S ratio |
3.00 | 2.47 | 1.28 | 2.07 | |
P/FCF ratio |
0.00 | 0.00 | 0.00 | 0.00 | |
P/Operating CF |
(265.71) | 94.76 | (117.78) | 1,121.72 | |
P/B ratio |
2.95 | 2.41 | 1.16 | 1.80 | |
Price to Tangible BV |
181.39 | 0.00 | 37.05 | 58.64 | |
EV/Sales |
3.56 | 3.03 | 1.82 | 2.60 | |
EV/EBITDA |
160.04 | 0.00 | 0.00 | 0.00 | |
EV/Operating CF |
654.57 | 105.45 | 60.47 | 361.35 | |
EV/FCF |
(105.65) | (439.62) | (448.59) | (95.87) | |
Quick Ratio |
3.04 | 3.03 | 3.71 | 3.61 | |
Current Ratio |
3.53 | 3.60 | 4.42 | 4.26 | |
Net Debt/EBITDA |
27.36 | 32.27 | (107.27) | 54.18 | |
Debt/Assets |
27.51% | 27.97% | 25.42% | 25.14% | |
Debt/Equity |
0.47 | 0.48 | 0.41 | 0.41 | |
Asset Turnover |
0.57 | 0.56 | 0.51 | 0.49 | |
Operating CF/Net income |
1.18 | 8.92 | 0.48 | (0.14) | |
Capex/Depreciation |
(0.71) | (0.48) | (0.30) | (0.35) | |
Interest Coverage |
(6.27) | (12.51) | (30.50) | (22.39) | |
Research and Development Expense of Revenue |
4.71% | 5.34% | 5.11% | 4.83% | |
Selling, General and Administrative Expense of Revenue |
45.24% | 45.07% | 47.98% | 45.72% | |
Intangible Assets out of Total Assets |
0.57 | 0.59 | 0.60 | 0.60 | |
Share Based Compensation of Revenue |
4.22% | 4.07% | 5.16% | 4.23% | |
Graham Net Nets |
(0.07) | (0.10) | (0.15) | (0.10) | |
Graham Number |
0.00 | 0.00 | 0.00 | 0.00 | |
Earnings Yield |
(1.35%) | (2.74%) | (10.38%) | (7.14%) | |
Free Cash Flow Yield |
(1.12%) | (0.28%) | (0.32%) | (1.31%) | |
Revenue per Share |
1.63 | 1.56 | 1.45 | 1.48 | |
Operating CF per Share |
(0.07) | 0.15 | (0.06) | 0.01 | |
Capex per Share |
(0.09) | (0.06) | (0.04) | (0.05) | |
Free Cash Flow per Share |
(0.16) | 0.09 | (0.10) | (0.03) | |
Cash per Share |
1.08 | 1.12 | 1.13 | 1.25 | |
Shareholders Equity per Share |
6.23 | 6.06 | 6.42 | 6.53 | |
Interest Debt per Share |
0.00 | 0.00 | 0.00 | 0.00 | |
Book value per Share |
6.23 | 6.06 | 6.42 | 6.53 | |
Free Cash Flow |
(20.66) | 11.74 | (13.14) | (4.46) | |
Working Capital |
293.91 | 275.60 | 289.09 | 287.99 | |
Capital Expenditures |
(11.77) | (8.22) | (5.00) | (5.80) | |
Net Current Asset Value |
(166.20) | (185.03) | (144.09) | (146.98) | |
EV/EBIT |
0.00 | 0.00 | 0.00 | 0.00 | |
Capex to Sales |
0.06 | 0.04 | 0.03 | 0.03 | |
Price to Operating Income |
0.00 | 0.00 | 0.00 | 0.00 | |
| Other line items | |||||
Average Receivables |
184.35 | 164.27 | 159.32 | 154.89 | |
Average Payables |
27.77 | 24.22 | 21.05 | 22.35 | |
Average Inventory |
26.98 | 30.65 | 29.80 | 27.66 | |
Average Assets |
1,375.85 | 1,373.10 | 1,473.98 | 1,498.93 | |
Average Common Equity |
819.46 | 819.89 | 858.51 | 869.45 |
Columns are period end dates · fundamentals updated 2 Nov 2026